Rinitis alérgica persistente

1. Valovirta E, Myrseth SE, Palkonen S. The voice of the patients: allergic rhinitis is not a trivial disease. Curr Opin Allergy Clin Immunol. 2008;8:1–9.

2. Bousquet J, Khaltaev N, Cruz AA, et al. Allergic rhinitis and its impact on asthma (aria) 2008 update (in collaboration with the world health organization, ga(2)len and allergen). Allergy. 2008;86:8–160.

3. Bousquet J, Schünemann HJ, Hellings PW, et al. Macvia clinical decision algorithm in adolescents and adults with allergic rhinitis. J Allergy Clin Immunol. 2016;138:367–374. e2.

4. Klimek L, Bergmann KC, Biedermann T, et al. Visual analogue scales (vas): measuring instruments for the documentation of symptoms and therapy monitoring in cases of allergic rhinitis in everyday health care: position paper of the german society of allergology (aeda) and the german society of allergy and clinical immunology (dgaki), ent section, in collaboration with the working group on clinical immunology, allergology and environmental medicine of the german society of otorhinolaryngology, head and neck surgery (dghnokhc). Allergo J Int. 2017;26:16–24.

5. Spc dymista nasal spray. 2015. https://www.medicines.org.uk/emc/ medicine/27579. Accessed 8 Aug, 2017.

6. Klimek L, Bachert C, Mosges R, et al. Effectiveness of mp29-02 for the treatment of allergic rhinitis in real-life: results from a noninterventional study. Allergy Asthma Proc. 2015;36:40–47.

7. Agache I, Doros IC, Leru PM, Bucur I, Poenaru M, Sarafoleanu C. Mp-azeflu provides rapid and effective allergic rhinitis control: results of a non-interventional study in romania. Rhinology. 2018;56:33–41.

8. Dollner R, Lorentz Larsen P, Dheyauldeen S, Steinsvag S. A multicenter, prospective, noninterventional study in a norwegian cohort of patients with moderate-to-severe allergic rhinitis treated with mp-azeflu. Allergy Rhinol (Providence). 2017;8:148–156.

9. Klimek L, Bachert C, Stjarne P, et al. Mp-azeflu provides rapid and effective allergic rhinitis control in real life: a pan-european study. Allergy Asthma Proc. 2016;37:376–386.

10. Meltzer E, Ratner P, Bachert C, et al. Clinically relevant effect of a new intranasal therapy (mp29-02) in allergic rhinitis assessed by responder analysis. Int Arch Allergy Immunol. 2013;161:369–377.

11. Price D, Shah S, Bhatia SB, et al. A new therapy (mp29-02) is effective for the long-term treatment of chronic rhinitis. J Investig Allergol Clin Immunol. 2013;23:495–503.

12. Bousquet PJ, Combescure C, Klossek JM, Daures JP, Bousquet J. Change in visual analog scale score in a pragmatic randomized cluster trial of allergic rhinitis. J Allergy Clin Immunol. 2009;123:1349–1354.

13. Demoly P, Bousquet PJ, Mesbah K, Bousquet J, Devillier P. Visual analogue scale in patients treated for allergic rhinitis: an observational prospective study in primary care: asthma and rhinitis. Clin Exp Allergy. 2013;43:881–888.

14. Bellanti JA, Settipane RA. The burden of allergic rhinitis on patients' quality of life. Allergy Asthma Proc. 2012;33:S112.

15. Bousquet PJ, Demoly P, Devillier P, Mesbah K, Bousquet J. Impact of allergic rhinitis symptoms on quality of life in primary care. Int Arch Allergy Immunol. 2013;160:393–400.